Exosome Secretion Drives Chemo‐Resistance of Temozolomide in Glioblastoma
Journal of Extracellular Biology · 2026-07 · 5 (7)
DOI: 10.1002/jex2.70161 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Biology, online erschienen am 30.06.2026. Verfasst von Wenpei Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering School of Life Science School of Interdisciplinary Science Key Laboratory of Molecular Medicine and Biot…. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality, Beijing Institute of Technology Research Fund Program for Young Scholars.
Abstract (Originalsprache)
Temozolomide (TMZ) is a first‐line chemotherapeutic agent for the treatment of glioblastoma (GBM), while a majority of patients do not effectively respond to TMZ owing to the multiple resistance mechanisms. In this study, we found that TMZ treatment substantially increased the exosome secretion from GBM cell line. The secreted exosomes from TMZ‐treated C6 cells maintained typical physicochemical properties, with only slight fluctuation in expression profile of surface markers compared to untreated cell‐derived exosomes. Further investigation revealed that increased expression of p53 might be the predominant reason to promote exosome secretion, potentially through the upregulation of six‐transmembrane epithelial antigen of prostate 3 (STEAP3) expression under stress condition. Moreover, we identified that pre‐treatment with TMZ‐induced exosomes could reduce the sensitivity of C6 cells to TMZ and considered that exosome secretion may serve as a potent TMZ resistance mechanism via enhancing anti‐apoptotic ability of GBM cells towards TMZ exposure. Proteomics analysis revealed a strategic mechanism to resist TMZ‐induced apoptosis by upregulating exosomal proteins associated with biogenesis, chemoresistance, and therapeutic adaption. This finding revealed a considerable TMZ resistance mechanism and provided a new inspiration for preventing exosome biogenesis to resensitise TMZ cytotoxicity towards GBM.
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering School of Life Science School of Interdisciplinary Science Key Laboratory of Molecular Medicine and Biotherapy Key Laboratory of Medical Molecule Science and Pharmaceutics En…
- School of Medical Engineering School of Interdisciplinary Science; Affiliated Zhuhai People's Hospital Beijing Institute of Technology Zhuhai P.R. China.
- Advanced Technology Research Institute Beijing Institute of Technology Ji'nan China.
- Beijing Key Laboratory of Mucosal Immunity Vaccines Against Respiratory Viruses Beijing Institute of Technology Beijing China.
ORCID-Profile: Shaobo Ruan
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
- Beijing Institute of Technology Research Fund Program for Young Scholars
Zitieren
APA
Li, W., Jiang, S., Liu, K., Li, Z., Yang, J., Liu, W., Huang, Y., Yang, M., Guo, S., & Ruan, S. (2026). Exosome Secretion Drives Chemo‐Resistance of Temozolomide in Glioblastoma. Journal of Extracellular Biology, 5(7). https://doi.org/10.1002/jex2.70161
Vancouver
Li W, Jiang S, Liu K, Li Z, Yang J, Liu W, et al. Exosome Secretion Drives Chemo‐Resistance of Temozolomide in Glioblastoma. Journal of Extracellular Biology. 2026;5(7). doi:10.1002/jex2.70161
BibTeX
@article{Li2026,
author = {Li, Wenpei and Jiang, Shaoping and Liu, Kun and Li, Zhi and Yang, Jun and Liu, Weimin and Huang, Yuanyu and Yang, Minghui and Guo, Shuai and Ruan, Shaobo},
title = {Exosome Secretion Drives Chemo‐Resistance of Temozolomide in Glioblastoma},
journal = {Journal of Extracellular Biology},
year = {2026},
volume = {5},
number = {7},
doi = {10.1002/jex2.70161}
}
EUVIMED